Xtampza Not Infringing 2 OxyContin Patents, Judge Says

By Alison Noon (October 1, 2018, 9:17 PM EDT) -- An opioid painkiller designed to deter sniffing and injection does not infringe two of Purdue Pharma LP's OxyContin-related patents, a Massachusetts federal judge has ruled in a victory for Collegium Pharmaceutical Inc. and its two-year-old Xtampza XR.

U.S. District Judge F. Dennis Saylor granted summary judgment Friday in favor of Collegium on claims arising from two patents involving abuse-deterrent properties such as a hard tablet that resists crushing and a gelling agent to impede snorting and injecting. He allowed claims involving a third patent focused on OxyContin's formula to go forward, despite his "considerable misgivings" about some of them.

Collegium uses...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!